Transparency Council: They will evaluate drugs for MS and hepatitis C, among others.

Agenda:

1. Preparation of a position paper on the evaluation of the drug Skyclarys (omaveloxolonum) under the drug program: "Treatment of patients with Friedreich's ataxia" (ICD-10: G11.1).
2. Preparation of an opinion on the assessment of the appropriateness of changes within the drug program B.71 "Treatment with interferon-free therapy for patients with chronic hepatitis C". (ICD-10: B18.2).
3. Preparation of an opinion on the assessment of the appropriateness of changes for cladribine under drug program B.29 "Treatment of patients with multiple sclerosis" (ICD-10: G35).
4. Preparation of an opinion on the draft health policy program of the local government unit "Program of therapeutic rehabilitation of seniors - residents of the municipality of Święciechowa aged 60 and over for 2025-2027".
5. Preparation of an opinion on the continuation of reimbursement in off-label indications for medicinal products containing the active substance Sirolimusum for indications:
   
   • tuberous sclerosis,
   • lymphangioleiomyomatosis,
   • Epithelioid epithelioid cell neoplasm.

6 Prepare an opinion on the continuation of reimbursement in off-label indications for medicinal products containing the active substance Ciclosporinum for indications:

7 Prepare an opinion on the continuation of reimbursement in off-label indications for medicinal products containing the active substance Cyclophosphamidum for indications:

8 Prepare an opinion on the continuation of reimbursement in off-label indications for medicinal products containing the active substance Danazolum for indications:

9. Preparation of an opinion on the continuation of reimbursement in off-label indications for medicinal products containing the active substance Valganciclovirum in the indication:

Source: AOTMiT